Zsírmáj (MASLD/MASH): vizsgálatok itt: Új-Zéland
6 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Christchurch, Grafton, Hamilton, Papatoetoe
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Christchurch, Grafton, Hamilton, Papatoetoe
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Auckland, Whangarei
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Wellington
- Életkor
- 18 év to 75 év
- People
- 1250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - 1/2. fázisTaking peopleA Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Where
- Auckland
- Életkor
- 18 év to 75 év
- People
- 56 worldwide
- Run by
- Kriya Therapeutics, Inc.
See details and how to joinNCT07732400 - 3. fázisTaking peopleA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Where
- Wellington
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221227